Clik here to view.
Investor Perception Study Predicts Future of Biotech Sector
The BIO/Thomson Reuters Investor Perception Study is an in-depth assessment of Wall Street’s views of the biotech industry, its current challenges, its relative valuation, and the outlook for 2009. The...
View ArticleClik here to view.
Big Changes for 1×1 Partnering – Investor Profiles
As BIO CEO approaches (February 14-15, 2011!), the BIO Partnering Team is proud to present several improvements to the 1×1 Partnering System. One of the most noticeable changes so far is the new...
View ArticleClik here to view.
A Very Big BTK January
We all heard reports that January was a great start to 2012 for the stock market, and even more so for Biotech. But how big was it, really? The Amex Biotech Index (the “BTK“) had its biggest January on...
View ArticleClik here to view.
Picks and Pans – The Buy-Side View for 2012
What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies? At the BIO CEO & Investor...
View ArticleClik here to view.
BIO Technology Transfer Symposium: Funding that First $2 Million
With creative funding schemes picking up steam and nontraditional funders taking an interest in biotech, what can universities and start-ups expect in their right first-round financing structure? At...
View ArticleClik here to view.
BIO Investor Forum: The New Kids on the Biotech Block
Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off...
View ArticleIt Takes a Village: The New Pharma-VC Model for Biotech Investing
High-profile funding collaborations between pharmaceutical companies and traditional venture capital funds have made headlines in recent months, pooling resources and expertise in an attempt to source...
View ArticleData Exclusivity Protects Innovators and Assures Investors
Biotechnology companies must have some certainty that they can protect their investment in the development of new breakthrough therapies for a substantial period of time. This protection helps...
View ArticleClik here to view.
The Year Ahead for Business Development Events
2013 is officially here (insert stale End-of-the-World joke). And as such, planning has been in full effect for BIO events. Here’s a recap of what’s coming up in the next few months. BIO’s in San Fran...
View ArticleClik here to view.
Biotech Hall of Fame: Interview with Biotech’s First Investment Banker
Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future....
View ArticleClik here to view.
#BIF13 Company Snapshot: AM-Pharma
The BIO Investor Forum will be taking place this October in San Francisco for its 12th annual event. So far this year, the hot topic is, of course, the hot market. Out of all the therapeutic US...
View ArticleEmerging Company Policy Deconstructed: Start-up Jobs and Innovation Act (S....
In a nutshell: Senators Robert Menendez (D-NJ) and Pat Toomey (R-PA) introduced the Start-up Jobs and Innovation Act to spur capital formation for R&D-focused companies in the early stages of...
View ArticleEmerging Company Policy Deconstructed: Small Cap Liquidity Reform Act (H.R....
In a nutshell: This bill, sponsored by Reps. Sean Duffy (R-WI) and John Carney (D-DE), will spur capital formation by increasing liquidity for emerging growth companies, including biotech innovators,...
View ArticleEmerging Company Policy Deconstructed: Fostering Innovation Act (H.R. 2629)
In a nutshell: Representative Michael Fitzpatrick (R-PA) introduced H.R. 2629, the Fostering Innovation Act, to update SEC filing status classifications for public companies and help ease regulatory...
View ArticleVIDEO: Public Policies to Promote the Innovation Economy
What can lawmakers do to make the US more competitive globally and encourage investment in groundbreaking R&D companies? Earlier today, the Coalition of Small Business Innovators held a forum at...
View ArticleClik here to view.
What’s Behind the Biotech IPO Boom?
Everyone knows that it’s been a knock-out year for the biotech sector in the public markets, which includes a large and well-performing IPO class. So far in 2013, 39 US-based companies have gone...
View ArticleClik here to view.
#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?
Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting...
View ArticleClik here to view.
Stable Policy Can Help Assure Unwavering Investment in U.S. Biofuels
The Renewable Fuel Standard (RFS) is a unique federal policy that has, just as its bipartisan supporters intended, spurred major domestic and international investment in US biofuels production and it...
View ArticleClik here to view.
Biotech Stocks: Perspective in a Bull Market
Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry....
View ArticleBIO CEO & Investor Conference Closes with Record Breaking Partnering Numbers
The 17th Annual BIO CEO & Investor Conference, the largest investor conference focused on established and emerging publicly traded and select private biotech companies, took place last week in New...
View Article
